Abbvie (NYSE:ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month. The company shares traded in a range of $148.89 to $154.47 on a day volume of 6.84 million shares, closed regular trading session at $149.57.
The National Institute for Health and Care Excellence (NICE) has issued guidance that recommends Rhythm Pharmaceuticals' (NASDAQ:RYTM) IMCIVREE (setmelanotide) as an option for treating obesity and controlling hunger caused by pro-opiomelanocortin (POMC) deficiency. The company shares traded in a range of $10.09 to $11.59 on a day volume of 7.29 million shares, closed regular trading session at $11.38. The company shares are currently trading at $11.21, down 1.49 percent in the after-hours trading session
